Kawajiri Hidemi, Takashima Tsutomu, Onoda Naoyoshi, Kashiwagi Shinichiro, Noda Satoru, Ishikawa Tetsurou, Wakasa Kenichi, Hirakawa Kosei
Departments of Surgical Oncology and.
Oncol Lett. 2012 Oct;4(4):612-616. doi: 10.3892/ol.2012.801. Epub 2012 Jul 13.
Sequential administration of anthracyclin and taxane for neoadjuvant chemotherapy (NAC) is the standard treatment for operable breast cancer. The pathological complete response (pCR) is a significant predictor of overall survival (OS), regardless of treatment. In this study, the pCR rate was retrospectively examined and compared with the treatment efficacy and the characteristics of pCR patients were analyzed. A total of 54 female patients with operable breast cancer, treated with FEC 100 followed by weekly paclitaxel between December 2005 and May 2009 at the Osaka City University Hospital, Osaka, Japan, were retrospectively reviewed. A total of 21 patients (39%) achieved pCR. The overall response rate was 91%. Only one patient had progressive disease. The pCR rate was significantly higher in those patients with estrogen receptor (ER)- and progesterone receptor (PR)-negative tumors and in those patients who completed the treatment course. An NAC regimen incorporating FEC 100 followed by weekly paclitaxel is effective for treating operable breast cancer.
蒽环类药物和紫杉烷序贯用于新辅助化疗（NAC）是可手术乳腺癌的标准治疗方法。无论采用何种治疗方式，病理完全缓解（pCR）都是总生存期（OS）的重要预测指标。在本研究中，回顾性检查了pCR率，并与治疗效果进行比较，同时分析了pCR患者的特征。对2005年12月至2009年5月期间在日本大阪市立大学医院接受FEC 100方案治疗后序贯每周紫杉醇治疗的54例可手术乳腺癌女性患者进行了回顾性研究。共有21例患者（39%）达到pCR。总缓解率为91%。仅有1例患者疾病进展。雌激素受体（ER）和孕激素受体（PR）均阴性的肿瘤患者以及完成治疗疗程的患者的pCR率显著更高。包含FEC 100方案后序贯每周紫杉醇的NAC方案对治疗可手术乳腺癌有效。
